Panbela Therapeutics initiated with a Buy at H.C. Wainwright

H.C. Wainwright initiated coverage of Panbela Therapeutics with a Buy rating and $7 price target. The analyst says Panbela leads the pack on polyamine-targeted therapy. Panbela’s approach "holds promise" and can reignite interest in the field through its multi-targeted approach to attacking metabolic dysregulation, the analyst tells investors in a research note. The firm says the company’s approach has shown favorable adverse event profiles across multiple indications.